Patents Assigned to Universite Paris-SUD XI
-
Patent number: 10867237Abstract: An artificial neuron includes a single-component electric dipole including a single material which belongs to the class of Mott insulators and is connected to first and second electric electrodes.Type: GrantFiled: April 24, 2015Date of Patent: December 15, 2020Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE—CNRS, UNIVERSITE DE NANTES, UNIVERSITE PARIS-SUD XIInventors: Laurent Cario, Benoit Corraze, Pablo Stoliar, Julien Tranchant, Etienne Janod, Marie-Paule Besland, Marcelo Rozenberg
-
Patent number: 10111961Abstract: Microparticles and nanoparticles of hydrophobized proteins and an alpha-cyclodextrin, obtained by auto-association in an aqueous medium, the hydrophobized protein being obtained by grafting of alkyl chains coming from fatty acids, by an acylation reaction. These microparticles and nanoparticles constitute systems used for encapsulation of active substances of interest, in particular in the pharmaceutical field, and the vectorization thereof for therapeutic purposes.Type: GrantFiled: May 2, 2014Date of Patent: October 30, 2018Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE PARIS-SUD XIInventor: Kawthar Bouchemal
-
Patent number: 9974852Abstract: A pharmaceutical composition includes, as active substance a mutated non-primate lentiviral Env protein having decreased immunosuppressive properties, substantially no immunosuppressive properties or no immunosuppressive properties, or a variant of the mutated lentiviral Env protein, or a fragment of the above proteins, in association with a pharmaceutically acceptable carrier.Type: GrantFiled: June 6, 2014Date of Patent: May 22, 2018Assignees: VIROXIS SAS, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT GUSTAVE ROUSSY, UNIVERSITE PARIS-SUD XIInventor: Thierry Heidmann
-
Patent number: 9868809Abstract: Giant p-(R)calixarenes, a process for the preparation of giant p-(R)calixarenes with high yields, and their use as the constitution of a material or in the context of the reinforcement of the material.Type: GrantFiled: August 28, 2013Date of Patent: January 16, 2018Assignee: UNIVERSITE PARIS-SUD XIInventors: Vincent Germain Huc, Cyril Martini
-
Patent number: 9809523Abstract: A process for the high-yield preparation of p-(R)calix[9-20]arenes.Type: GrantFiled: February 27, 2015Date of Patent: November 7, 2017Assignees: UNIVERSITE PARIS-SUD XI, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUEInventors: Vincent Germain Huc, Cyril Martini
-
Patent number: 9682137Abstract: A pharmaceutical composition includes, as active substance a mutated lentiviral ENV protein, substantially devoid of immunosuppressive properties or a variant of the mutated lentiviral ENV protein or a fragment of the above proteins, in association with a pharmaceutically acceptable carrier.Type: GrantFiled: December 7, 2012Date of Patent: June 20, 2017Assignees: VIROXIS SAS, CENTRE NATIONAL DE LA RECHARCHE SCIENTIFIQUE, UNIVERSITE PARIS-SUD XI, INSTITUT GUSTAVE ROUSSYInventor: Thierry Heidmann
-
Patent number: 9636396Abstract: A pharmaceutical composition includes, as active substance a mutated lentiviral ENV protein, substantially devoid of immunosuppressive properties or a variant of the mutated lentiviral ENV protein or a fragment of the above proteins, in association with a pharmaceutically acceptable carrier.Type: GrantFiled: December 7, 2012Date of Patent: May 2, 2017Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE PARIS-SUD XI, INSITUT GUSTAVE ROUSSY, VIROXIS S.A.S.Inventor: Thierry Heidmann
-
Patent number: 9593153Abstract: The present invention relates to polypeptides and their uses as apelin inhibitors. More particularly, the present invention relates to a polypeptide comprising the sequence as set forth in SEQ ID NO:1 wherein at least one arginine residue at position 18, 19, 22 or 23 has been substituted or deleted.Type: GrantFiled: April 9, 2013Date of Patent: March 14, 2017Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE PARIS-SUD XI, UNIVERSITE DE BORDEAUXInventors: Geraldine Siegfried, Abdel-Majid Khatib
-
Patent number: 9376362Abstract: A process for the high-yield preparation of p-(R-oxy)calix[9-20]arenes from a mixture of a base, a phenol, a source of formaldehyde and a organic solvent, p-(R-oxy)calix[9-20]arenes obtained from such a process, and uses of such p-(R-oxy)calix[9-20]arenes.Type: GrantFiled: August 28, 2013Date of Patent: June 28, 2016Assignee: UNIVERSITE PARIS-SUD XIInventors: Vincent Germain Huc, Cyril Martini
-
Patent number: 9295630Abstract: A complex formed of at least one molecule of 5-(1,2-dihydroxy-ethyl)-3,4-dihydroxy-5H-furan-2-one or a derivative covalently bonded with at least one hydrocarbon radical with formula (A) as follows: wherein: •-m 1=1, 2, 3, 4, 5 or 6; •-m 2=0, 1, 2, 3, 4, 5 or 6; and represents the site of the bond with the molecule of 5-(1,2-dihydroxy-ethyl)-3,4-dihydroxy-5H-furan-2-one or derivative.Type: GrantFiled: March 14, 2013Date of Patent: March 29, 2016Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE PARIS SUD XIInventors: Patrick Couvreur, Fatima Zouhiri, Ruxandra Gref, Didier Desmaele
-
Patent number: 9255054Abstract: The high-yield synthesis of p-(benzyloxy)calix[6,7,8]arenes by bringing caesium hydroxide into contact with p-(benzyloxy)phenol and paraformaldehyde, and composite materials including these p-(benzyloxy)calix[6,7,8]arenes.Type: GrantFiled: December 11, 2012Date of Patent: February 9, 2016Assignee: UNIVERSITE PARIS-SUD XIInventors: Vincent Germain Huc, Cyril Martini
-
Patent number: 9181204Abstract: The present invention relates to compounds of formula (I): A-T-Z??(I) in which: the group A is a bipyridine group capable of complexing at least one metal element; the group T is a triazole group directly bound to the group A; and the group Z is a halogen atom, a nitro group, a cyano group, an alkyl group, an aryl group, a heterocyclic group, a group of formula —NR1R2, a group of formula —SR1, a group of formula —S(?O)2(OR1), a group of formula —O—S(?O)2(OR1), a group of formula —O—S(?O)2(R1), a group of formula —S(?O)(OR1), a group of formula —S(?O)(R1), a group of formula —S(?O)2R1, a group of formula —PR1R2, a group of formula —P(?O)(OR1)(OR2), a group of formula —O—P(?O)(OR1)(OR2), a group of formula —O—P(?O)(OR1)(R2), a group of formula —OR1 or a group of formula —CO—R1.Type: GrantFiled: December 7, 2010Date of Patent: November 10, 2015Assignees: Commissariat a l'energie atomique et aux energies alternatives, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE PARIS SUD XIInventors: Winfried Leibl, Boris Vauzeilles, Aurelie Baron, Ally Aukauloo, Christian Herrero, Marie-France Charlot
-
Publication number: 20150291494Abstract: A process for the high-yield preparation of p-(R-oxy)calix[9-20]arenes from a mixture of a base, a phenol, a source of formaldehyde and a organic solvent, p-(R-oxy)calix[9-20]arenes obtained from such a process, and uses of such p-(R-oxy)calix[9-20]arenes.Type: ApplicationFiled: August 28, 2013Publication date: October 15, 2015Applicant: UNIVERSITE PARIS-SUD XIInventors: Vincent Germain HUC, Cyril MARTINI
-
Patent number: 9093163Abstract: A method of operating a magnetoresistive device is described. The device comprises a ferromagnetic region configured to exhibit magnetic anisotropy and to allow magnetisation thereof to be switched between at least first and second orientations and a gate capacitively coupled to the ferromagnetic region. The method comprises applying an electric field pulse to the ferromagnetic region so as to cause orientation of magnetic anisotropy to change for switching magnetisation between the first and second orientations.Type: GrantFiled: January 14, 2010Date of Patent: July 28, 2015Assignees: HITACHI, LTD., UNIVERSITE PARIS SUD XI, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUEInventors: Joerg Wunderlich, Jan Zemen, Claude Chappert, Bryan Gallagher, Thibaut Devolder, David Williams
-
Methods and pharmaceutical compositions for the treatment of cardiomyopathy due to friedreich ataxia
Patent number: 9066966Abstract: A method for preventing or treating cardiomyopathy due to energy failure in a subject in need thereof is provided. The method comprises administering to the subject a therapeutically effective amount of a vector which comprises a nucleic acid sequence encoding a gene that can reverse energy failure. An exemplary cardiomyopathy is that which is associated with Friedreich ataxia and an exemplary nucleic acid sequence comprises a nucleic acid that encodes frataxin (FXN).Type: GrantFiled: February 1, 2013Date of Patent: June 30, 2015Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), CNRS (Centre National de la Recherche Scientifique), Universite de Strasbourg, Cornell University, Universite Paris-Sud XI, Assistance Publique-Hopitaux de Paris (APHP)Inventors: Helene Monique Puccio, Patrick Aubourg, Ronald G. Crystal, Pierre Bougneres -
Publication number: 20150140010Abstract: The present invention relates to methods for diagnosing and treating focal segmental glomerulosclerosis. More particularly, the present invention relates to a method for determining whether a subject is at risk of having or developing a focal segmental glomerulosclerosis (FSGS) comprising the step consisting of determining the level of calcium/calmodulin-dependent serine protein kinase (CASK) in a blood sample obtained from the subject. The present invention also relates to an agent effective to inhibit the binding of CASK to hCD98 present on the surface of podocytes for use in the prevention or treatment of focal segmental glomerulosclerosis (FSGS) in a subject in need thereof.Type: ApplicationFiled: May 22, 2013Publication date: May 21, 2015Applicants: INSERM 9INSTITUT NATIONAL DE LA SANTE ET DE LA R- ECHERCHE MEDICALE), UNIVERSITE PARIS-SUD XI, ASSISTANCE PUBLIQUE-HOPITAUX DE PARISInventors: Antoine Durrbach, Hanz Lorenzo, Severine Beaudreuil
-
Publication number: 20150133323Abstract: Disclosed is a method for characterization, in a biological sample, of circulating tumour cells (CTCs) bearing at least one marker characteristic of the tumorous nature of the cell, the marker being selected from the groups constituted by: the oncogenic proteins characteristic of the CTCs, and the tumour markers. Also disclosed is the use of this method for deciding on the implementation of a treatment for a cancer patient.Type: ApplicationFiled: November 19, 2012Publication date: May 14, 2015Applicants: UNIVERSITE PARIS SUD XI, INSTITUT GUSTAVE ROUSSYInventors: Amélie Barthelemy, Francoise Farace, Marianne Oulhen, Jean-Charles Soria, Alexander Valent, Philippe Vielh, Benjamin Besse, Emma Pailler
-
Publication number: 20150011798Abstract: The high-yield synthesis of p-(benzyloxy)calix[6,7,8]arenes by bringing caesium hydroxide into contact with p-(benzyloxy)phenol and paraformaldehyde, and composite materials including these p-(benzyloxy)calix[6,7,8]arenes.Type: ApplicationFiled: December 11, 2012Publication date: January 8, 2015Applicant: UNIVERSITE PARIS-SUD XIInventors: Vincent, Germain Huc, Cyril Martini
-
Publication number: 20140294880Abstract: A pharmaceutical composition includes, as active substance a mutated lentiviral ENV protein, substantially devoid of immunosuppressive properties or a variant of the mutated lentiviral ENV protein or a fragment of the above proteins, in association with a pharmaceutically acceptable carrier.Type: ApplicationFiled: December 7, 2012Publication date: October 2, 2014Applicants: VIROXIS S.A.S., INSTITUT GUSTAVE ROUSSY, UNIVERSITE PARIS-SUD XI, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUEInventor: Thierry Heidmann
-
Patent number: 8795685Abstract: Described is the use of a mutation of at least one amino acid in the immunosuppressive domain of a HIV or SIV accessory protein, for modulating the immunosuppressive property of the protein.Type: GrantFiled: August 17, 2005Date of Patent: August 5, 2014Assignees: Institut Gustave Roussy, Centre National de la Recherche Scientifique, Universite Paris Sud XIInventors: Martial Renard, Marianne Mangeney, Thierry Heidmann